Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STIMULATE-ICP Long COVID integrated care pathway and nested drug trial
ISRCTN10665760Phase 3Completed
- Sponsor
- University College London
- Start
- Aug 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of loratadine, famotidine, colchicine and rivaroxaban in post-COVID syndrome and coronavirus disease 2019 (COVID-19) (4 arms), sponsored by University College London. Primary endpoint: Fatigue measured using the Fatigue Assessment Scale. Started Aug 2022; status: completed.
02
Drugs
loratadinefamotidinecolchicinerivaroxaban
03
Conditions
post-COVID syndromecoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN10665760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10665760.